NGR-hTNF and Doxorubicin as Second-Line Treatment of Patients with Small Cell Lung Cancer

V Gregorc, R Cavina, S Novello, F Grossi, C Lazzari, E Capelletto, C Genova, G Salini, A Lambiase, A Santoro

Research output: Contribution to journalArticle

Abstract

Background: Relapsed small cell lung cancer (SCLC) patients have limited treatment options and poor outcomes. NGR-hTNF is a vascular-targeting agent, which increases intratumoral chemotherapy penetration and T-lymphocyte infiltration. Methods: Twenty-eight patients relapsing after at least one platinum-based regimen with a treatment-free interval shorter (n = 16; platinum-resistant) or longer (n = 12; platinum-sensitive) than 3 months received NGR-hTNF 0.8 μg/m2plus doxorubicin 75 mg/m2every 3 weeks. The primary endpoint of this single-arm phase II trial was progression-free survival (PFS), and safety, response rate, and survival were secondary endpoints. Results: The most common grade 3–4 toxicities were neutropenia (53%) and anemia (21%). Median PFS was 3.2 months for all patients, 2.7 months for platinum-resistant patients, and 4.1 months for platinum-sensitive patients. Seven patients had partial responses (25%), including four (25%) with platinum-resistant and three (25%) with platinum-sensitive relapse. Mean changes from baseline in tumor burden (after two, four, and six cycles) did not differ between platinum-resistant (−9%, −29%, and −32%) and platinum-sensitive (−11%, −20%, and −43%) cohorts. Overall survival was associated only with baseline lymphocyte counts, with median survival times of 13.1 and 5.2 months for lymphocyte counts above or below the median, respectively. Conclusion: NGR-hTNF plus doxorubicin showed manageable toxicity and promising activity in patients with relapsed SCLC. © AlphaMed Press; the data published online to support this summary is the property of the authors.
Original languageEnglish
Pages (from-to)1133-e112
JournalOncologist
Volume23
Issue number10
DOIs
Publication statusPublished - 2018

Fingerprint

Small Cell Lung Carcinoma
Platinum
Doxorubicin
Therapeutics
Lymphocyte Count
Disease-Free Survival
tumor necrosis factor-alpha, CNGRC fusion protein, human
Survival
Neutropenia
Tumor Burden
Blood Vessels
Anemia
Survival Rate
T-Lymphocytes
Safety
Recurrence
Drug Therapy

Cite this

Gregorc, V., Cavina, R., Novello, S., Grossi, F., Lazzari, C., Capelletto, E., ... Santoro, A. (2018). NGR-hTNF and Doxorubicin as Second-Line Treatment of Patients with Small Cell Lung Cancer. Oncologist, 23(10), 1133-e112. https://doi.org/10.1634/theoncologist.2018-0292

NGR-hTNF and Doxorubicin as Second-Line Treatment of Patients with Small Cell Lung Cancer. / Gregorc, V; Cavina, R; Novello, S; Grossi, F; Lazzari, C; Capelletto, E; Genova, C; Salini, G; Lambiase, A; Santoro, A.

In: Oncologist, Vol. 23, No. 10, 2018, p. 1133-e112.

Research output: Contribution to journalArticle

Gregorc, V, Cavina, R, Novello, S, Grossi, F, Lazzari, C, Capelletto, E, Genova, C, Salini, G, Lambiase, A & Santoro, A 2018, 'NGR-hTNF and Doxorubicin as Second-Line Treatment of Patients with Small Cell Lung Cancer', Oncologist, vol. 23, no. 10, pp. 1133-e112. https://doi.org/10.1634/theoncologist.2018-0292
Gregorc, V ; Cavina, R ; Novello, S ; Grossi, F ; Lazzari, C ; Capelletto, E ; Genova, C ; Salini, G ; Lambiase, A ; Santoro, A. / NGR-hTNF and Doxorubicin as Second-Line Treatment of Patients with Small Cell Lung Cancer. In: Oncologist. 2018 ; Vol. 23, No. 10. pp. 1133-e112.
@article{4e1b7c6f77af4ad987ec4bfee42a5023,
title = "NGR-hTNF and Doxorubicin as Second-Line Treatment of Patients with Small Cell Lung Cancer",
abstract = "Background: Relapsed small cell lung cancer (SCLC) patients have limited treatment options and poor outcomes. NGR-hTNF is a vascular-targeting agent, which increases intratumoral chemotherapy penetration and T-lymphocyte infiltration. Methods: Twenty-eight patients relapsing after at least one platinum-based regimen with a treatment-free interval shorter (n = 16; platinum-resistant) or longer (n = 12; platinum-sensitive) than 3 months received NGR-hTNF 0.8 μg/m2plus doxorubicin 75 mg/m2every 3 weeks. The primary endpoint of this single-arm phase II trial was progression-free survival (PFS), and safety, response rate, and survival were secondary endpoints. Results: The most common grade 3–4 toxicities were neutropenia (53{\%}) and anemia (21{\%}). Median PFS was 3.2 months for all patients, 2.7 months for platinum-resistant patients, and 4.1 months for platinum-sensitive patients. Seven patients had partial responses (25{\%}), including four (25{\%}) with platinum-resistant and three (25{\%}) with platinum-sensitive relapse. Mean changes from baseline in tumor burden (after two, four, and six cycles) did not differ between platinum-resistant (−9{\%}, −29{\%}, and −32{\%}) and platinum-sensitive (−11{\%}, −20{\%}, and −43{\%}) cohorts. Overall survival was associated only with baseline lymphocyte counts, with median survival times of 13.1 and 5.2 months for lymphocyte counts above or below the median, respectively. Conclusion: NGR-hTNF plus doxorubicin showed manageable toxicity and promising activity in patients with relapsed SCLC. {\circledC} AlphaMed Press; the data published online to support this summary is the property of the authors.",
author = "V Gregorc and R Cavina and S Novello and F Grossi and C Lazzari and E Capelletto and C Genova and G Salini and A Lambiase and A Santoro",
year = "2018",
doi = "10.1634/theoncologist.2018-0292",
language = "English",
volume = "23",
pages = "1133--e112",
journal = "Oncologist",
issn = "1083-7159",
publisher = "Wiley Blackwell",
number = "10",

}

TY - JOUR

T1 - NGR-hTNF and Doxorubicin as Second-Line Treatment of Patients with Small Cell Lung Cancer

AU - Gregorc, V

AU - Cavina, R

AU - Novello, S

AU - Grossi, F

AU - Lazzari, C

AU - Capelletto, E

AU - Genova, C

AU - Salini, G

AU - Lambiase, A

AU - Santoro, A

PY - 2018

Y1 - 2018

N2 - Background: Relapsed small cell lung cancer (SCLC) patients have limited treatment options and poor outcomes. NGR-hTNF is a vascular-targeting agent, which increases intratumoral chemotherapy penetration and T-lymphocyte infiltration. Methods: Twenty-eight patients relapsing after at least one platinum-based regimen with a treatment-free interval shorter (n = 16; platinum-resistant) or longer (n = 12; platinum-sensitive) than 3 months received NGR-hTNF 0.8 μg/m2plus doxorubicin 75 mg/m2every 3 weeks. The primary endpoint of this single-arm phase II trial was progression-free survival (PFS), and safety, response rate, and survival were secondary endpoints. Results: The most common grade 3–4 toxicities were neutropenia (53%) and anemia (21%). Median PFS was 3.2 months for all patients, 2.7 months for platinum-resistant patients, and 4.1 months for platinum-sensitive patients. Seven patients had partial responses (25%), including four (25%) with platinum-resistant and three (25%) with platinum-sensitive relapse. Mean changes from baseline in tumor burden (after two, four, and six cycles) did not differ between platinum-resistant (−9%, −29%, and −32%) and platinum-sensitive (−11%, −20%, and −43%) cohorts. Overall survival was associated only with baseline lymphocyte counts, with median survival times of 13.1 and 5.2 months for lymphocyte counts above or below the median, respectively. Conclusion: NGR-hTNF plus doxorubicin showed manageable toxicity and promising activity in patients with relapsed SCLC. © AlphaMed Press; the data published online to support this summary is the property of the authors.

AB - Background: Relapsed small cell lung cancer (SCLC) patients have limited treatment options and poor outcomes. NGR-hTNF is a vascular-targeting agent, which increases intratumoral chemotherapy penetration and T-lymphocyte infiltration. Methods: Twenty-eight patients relapsing after at least one platinum-based regimen with a treatment-free interval shorter (n = 16; platinum-resistant) or longer (n = 12; platinum-sensitive) than 3 months received NGR-hTNF 0.8 μg/m2plus doxorubicin 75 mg/m2every 3 weeks. The primary endpoint of this single-arm phase II trial was progression-free survival (PFS), and safety, response rate, and survival were secondary endpoints. Results: The most common grade 3–4 toxicities were neutropenia (53%) and anemia (21%). Median PFS was 3.2 months for all patients, 2.7 months for platinum-resistant patients, and 4.1 months for platinum-sensitive patients. Seven patients had partial responses (25%), including four (25%) with platinum-resistant and three (25%) with platinum-sensitive relapse. Mean changes from baseline in tumor burden (after two, four, and six cycles) did not differ between platinum-resistant (−9%, −29%, and −32%) and platinum-sensitive (−11%, −20%, and −43%) cohorts. Overall survival was associated only with baseline lymphocyte counts, with median survival times of 13.1 and 5.2 months for lymphocyte counts above or below the median, respectively. Conclusion: NGR-hTNF plus doxorubicin showed manageable toxicity and promising activity in patients with relapsed SCLC. © AlphaMed Press; the data published online to support this summary is the property of the authors.

U2 - 10.1634/theoncologist.2018-0292

DO - 10.1634/theoncologist.2018-0292

M3 - Article

VL - 23

SP - 1133-e112

JO - Oncologist

JF - Oncologist

SN - 1083-7159

IS - 10

ER -